Pitfalls in the radiological response assessment of immunotherapy

被引：53

作者：

Beer L. ^{[1
]}

Hochmair M. ^{[2
]}

Prosch H. ^{[1
]}

机构：

[1] Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18–20, Vienna

[2] Respiratory Oncology Unit, Otto-Wagner Hospital, Vienna

来源：

memo - Magazine of European Medical Oncology | 2018年 / 11卷 / 2期

关键词：

Hyperprogression; Immune checkpoint inhibitor; PD-1; inhibitor; Pneumonitis; Pseudoprogression;

D O I：

10.1007/s12254-018-0389-x

中图分类号：

学科分类号：

摘要：

Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization criteria. Consequently, adaptions of these criteria have been released such as the immune-related RECIST and immune RECIST, which account for the specialities of immunotherapies. Immunotherapies can cause a distinct set of adverse events such as pneumonitis, colitis, and hypophysitis. In addition, atypical treatment response patterns termed pseudoprogression have been observed. Thereby, new or enlarging lesions appear after treatment start and mimic tumor progression, which is followed by an eventual decrease in total tumor burden. In this review article we will describe pitfalls in the radiological response assessment of immunotherapies, focusing on pseudoprogression and imaging appearances of common immune-related adverse events. © 2018, The Author(s).

引用

页码：138 / 143

页数：5

共 29 条

[1]

Kwak J.J., Et al., Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events, Radiographics, 35, 2, pp. 424-437, (2015)

[2]

Allen P.B., Gordon L.I., PD-1 blockade in Hodgkin’s lymphoma: learning new tricks from an old teacher, Expert Rev Hematol, 9, 10, pp. 939-949, (2016)

[3]

Sonpavde G., PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma, N. Engl. J. Med., 376, 11, (2017)

[4]

Rizvi N.A., Et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, 16, 3, pp. 257-265, (2015)

[5]

Nishino M., Et al., Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions, Clin Cancer Res, 23, 16, (2017)

[6]

Thallinger C., Et al., Review of cancer treatment with immune checkpoint inhibitors, Wien Klin Wochenschr, (2017)

[7]

Remon J., Et al., Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: current status and future approaches, Lung Cancer, 106, pp. 70-75, (2017)

[8]

Eisenhauer E., Et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 2, pp. 228-247, (2009)

[9]

Wolchok J.D., Et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 23, pp. 7412-7420, (2009)

[10]

Chiou V.L., Burotto M., Pseudoprogression and immune-related response in solid tumors, J Clin Oncol, 33, 31, pp. 3541-3543, (2015)

← 1 2 3 →